{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:19:50Z","timestamp":1787552390633,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of first-line therapies for peripheral T-cell lymphoma (PTCL) via network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) evaluating first-line treatments in untreated PTCL patients (up to March 1, 2025). Two investigators independently screened studies, extracted data, and assessed bias risk. Network meta-analysis was performed using R (v4.3.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven RCTs (1,334 patients) were included, evaluating CHOP, VIP-rABVD, GEM-P, A+CHP, GDPT, Ro-CHOP, and ICED. No significant differences were found in overall or progression-free survival. However, A+CHP (OR = 1.90, 95%CI:1.20\u20133.10) and GDPT (OR = 2.00, 95%CI:1.00\u20133.80) showed higher objective response rates versus CHOP. A+CHP (OR = 1.76, 95%CI:1.09\u20132.88) and Ro-CHOP (OR = 1.40, 95%CI:1.00\u20131.80) achieved better disease control. VIP-rABVD had the highest thrombocytopenia risk (OR = 50.0, 95%CI:14.29\u2013100), while ICED showed increased anemia risk (OR = 9.20, 95%CI:2.80\u201344.0). Subgroup analyses revealed no significant PFS differences in AITL\/PTCL-NOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A+CHP shows superior efficacy with acceptable toxicity, while GDPT improves responses but increases myelosuppression risk. Ro-CHOP enhances disease control but with limited remission depth and higher toxicity. Subtype analyses suggest potential PFS benefits for Ro-CHOP in AITL. For PTCL of unspecified type (PTCL-NOS), there is little difference in efficacy among the various treatment regimens.A+CHP and GDPT offer optimal benefit-risk profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1912842","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:32:59Z","timestamp":1787549579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy and safety of first-line therapies for peripheral T-cell lymphoma: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaxing","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Affiliated Hospital of Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"Wu","sequence":"additional","affiliation":[{"name":"West Campus of Hebei North University","place":["Zhangjiakou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchao","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17272","DOI":"10.1038\/s41598-021-96804-8","article-title":"Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016","volume":"11","author":"Hemminki","year":"2021","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27165","article-title":"Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management","volume":"99","author":"Ong","year":"2024","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-cell lymphoma: Molecular profiling recognizes subclasses and identifies prognostic markers","volume":"5","author":"Rodr\u00edguez","year":"2021","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2924","article-title":"Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/5.suppl_2.s91","article-title":"A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study","volume":"5","author":"Fisher","year":"1994","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): A phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral T-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021789","article-title":"Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02254-x","article-title":"Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: A systematic review and meta-analysis","volume":"59","author":"Girard","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1376\/jcm.20090918","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"B19","article-title":"Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): Additional considerations for cluster-randomized trials","volume":"10","author":"Eldridge","year":"2016","journal-title":"Cochrane Methods Cochrane Database Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/978-1-62703-059-5_25","article-title":"Bayesian inference","volume":"930","author":"Bois","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt043","article-title":"Markov chain Monte Carlo: An introduction for epidemiologists","volume":"42","author":"Hamra","year":"2013","journal-title":"Int J Epidemiol"},{"key":"B22","article-title":"NICE decision support unit technical support documents","volume-title":"Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment","author":"Dias","year":"2012"},{"key":"B23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12936-017-1963-0","article-title":"Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis","volume":"16","author":"Whegang Youdom","year":"2017","journal-title":"Malar J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920923829","article-title":"Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients","volume":"12","author":"Sun","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: Results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1230629","article-title":"Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: Final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B39","article-title":"Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis","volume":"61","author":"Fabris","year":"2001","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70187-x","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.beha.2013.04.003","article-title":"International analysis of the frequency and outcomes of NK\/T-cell lymphomas","volume":"26","author":"William","year":"2013","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1912842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:33:01Z","timestamp":1787549581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1912842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1912842"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1912842","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1912842"}}